Cue Biopharma (CUE) EBT Margin (2018 - 2026)

Cue Biopharma has disclosed EBT Margin across 9 years of filings, most recently posting 1111.31% for Q2 2026.

• In Q2 2026, EBT Margin fell 82570.0% year-over-year to 1111.31%; the TTM figure through Jun 2026 stood at 450.23% (up 1292.0% YoY), while the FY2025 annual figure was 93.73%, up 33566.0% from the prior year.
• EBT Margin came in at 1111.31% for Q2 2026 at Cue Biopharma, down from 22.48% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 22.48% in Q4 2025 to a low of 50800.0% in Q2 2022.
• Average EBT Margin over 5 years is 5485.71%, with a median of 709.88% recorded in 2023.
• Year-over-year, EBT Margin plunged 5042472 bps in 2022 and soared 4986274 bps in 2023.
• Over 5 years, EBT Margin stood at 9426.49% in 2022, then jumped by 92 bps to 709.88% in 2023, then advanced by 16 bps to 592.83% in 2024, then soared by 104 bps to 22.48% in 2025, then slumped by 5043 bps to 1111.31% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 1111.31% in Q2 2026, 22.48% in Q4 2025, and 343.09% in Q3 2025.